ReviewInfection and drug resistance2017
Drug resistance in influenza A virus: the epidemiology and management.
Review in Infection and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 251 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
251 citing papers in PubMed, 7 syntheses or guidelines pooled it, 442 citations in OpenAlex.
- Emerging trends and hotspots in Oseltamivir resistance: insights from a bibliometric investigation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Mortality Risk Among Patients With Influenza Illness Admitted to the ICU: A Systematic Review and Meta-Analysis.Influenza and other respiratory viruses · 2025Pooled it
- The effectiveness of interventions to reduce the transmission of acute respiratory infections in care homes: a systematic review.Journal of public health (Oxford, England) · 2024Pooled it
- A Systematic Review of Clinical Pharmacokinetics of Inhaled Antiviral.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Pooled it
- Anti-Influenza with Green Tea Catechins: A Systematic Review and Meta-Analysis.Molecules (Basel, Switzerland) · 2021Pooled it
- Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies.Frontiers in nutrition · 2021Pooled it
- A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.Antimicrobial agents and chemotherapy · 2025Trial
- NS1-Induced PARP1 Phase Transitions Prolongs Host Transcriptional Pausing to Promote Influenza A Virus Replication.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery.Chemical biology & drug design · 2026Review
- Article
- Validation of a Qualitative Detection Method for Influenza A Virus RNA Based on the RT-RPA-CRISPR/Cas13a System.Current microbiology · 2026Article
- A nanobody-based proteolysis-targeting chimera offers broad-spectrum protection against diverse influenza virus infections.Signal transduction and targeted therapy · 2026Article
- A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.Antimicrobial agents and chemotherapy · 2026Article
- Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6.Iranian biomedical journal · 2026Article
- DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification and characterization of a novel inhibitor of influenza A virus that acts by blocking nucleoprotein oligomerization.Antimicrobial agents and chemotherapy · 2026Article
- Genetic variation and vaccine match of influenza B virus in Riyadh, Saudi Arabia during three consecutive seasons, 2020-2023.Virus genes · 2026Article
- From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza.Frontiers in cellular and infection microbiology · 2026Review
- Proteomic Analysis of Influenza.Advances in experimental medicine and biology · 2026Review
191 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A virus (IAV) is the sole cause of the unpredictable influenza pandemics and deadly zoonotic outbreaks and constitutes at least half of the cause of regular annual influenza epidemics in humans. Two classes of anti-IAV drugs, adamantanes and neuraminidase (NA) inhibitors (NAIs) targeting the viral components M2 ion channel and NA, respectively, have been approved to treat IAV infections. However, IAV rapidly acquired resistance against both classes of drugs by mutating these viral components. The adamantane-resistant IAV has established itself in nature, and a majority of the IAV subtypes, especially the most common H1N1 and H3N2, circulating globally are resistant to adamantanes. Consequently, adamantanes have become practically obsolete as anti-IAV drugs. Similarly, up to 100% of the globally circulating IAV H1N1 subtypes were resistant to oseltamivir, the most commonly used NAI, until 2009. However, the 2009 pandemic IAV H1N1 subtype, which was sensitive to NAIs and has now become one of the dominant seasonal influenza virus strains, has replaced the pre-2009 oseltamivir-resistant H1N1 variants. This review traces the epidemiology of both adamantane- and NAI-resistant IAV subtypes since the approval of these drugs and highlights the susceptibility status of currently circulating IAV subtypes to NAIs. Further, it provides an overview of currently and soon to be available control measures to manage current and emerging drug-resistant IAV. Finally, this review outlines the research directions that should be undertaken to manage the circulation of IAV in intermediate hosts and develop effective and alternative anti-IAV therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.